| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO and Chairman | Director | President, CEO and Chairman
2 companies
David M Stack last filed a Form 4 in June 2023, as CEO and Chairman at PCRX. The filings on record cover 2 companies. David M Stack's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns David M Stack a middling insider score of 67/100, based on 9 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of -1.1%.
At the last filing, the largest reported position was 186,481 shares of PCRX. The PCRX filings lean toward selling, a net 785,290 shares.
David M Stack has 65 Form 4 filings on record from January 2015 to June 2023, across 2 companies: CEO and Chairman at Pacira BioSciences (PCRX), 2015–2023; Amarin Corp Plc\uk (AMRN), 2015–2021.
The 171 reported transactions were 75 open-market sales, 59 option exercises, 25 option or other derivative awards and 8 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $190K and 35 sales worth about $44.6M.
The largest open-market purchase was 25,000 shares of AMRN at an average $4.86 on November 30, 2020, about $122K.
The largest open-market sale was 90,000 shares of PCRX at an average $55.36 on October 16, 2020, about $5.0M.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 7, 2023 | PCRX Pacira Biosciences, Inc. | CEO and Chairman | Sell | 10,384 | $38.41 | $398,885.47 | -6.3% | -7.4% | -22.4% | |
| Jun 8, 2022 | PCRX Pacira Biosciences, Inc. | CEO and Chairman | Sell | 25,793 | $60.56 | $1,561,998.17 | -15.3% | -13.7% | -37.7% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | CEO and Chairman | Sell | 14,905 | $61.04 | $909,756.49 | -19.6% | -2.8% | +5.5% | |
| Jun 4, 2021 | AMRN Amarin Corp Plc\uk | Director | Buy | 15,000 | $4.56 | $68,465.00 | +60.0% | +21.3% | -62.2% | |
| May 12, 2021 | PCRX Pacira Biosciences, Inc. | CEO and Chairman | Sale+OE | 42,500 | $61.44 | $2,611,298.35 | -35.8% | -9.4% | -1.4% | |
| Feb 3, 2021 | PCRX Pacira Biosciences, Inc. | CEO and Chairman | Sale+OE | 42,500 | $70.31 | $2,988,133.00 | -35.8% | - | - | |
| Nov 30, 2020 | AMRN Amarin Corp Plc\uk | Director | Buy | 25,000 | $4.86 | $121,517.50 | New | - | - | |
| Oct 16, 2020 | PCRX Pacira Biosciences, Inc. | CEO and Chairman | Sale+OE | 90,000 | $55.36 | $4,982,700.00 | -34.2% | - | - | |
| Aug 17, 2020 | PCRX Pacira Biosciences, Inc. | CEO and Chairman | Sell | 15,000 | $61.91 | $928,619.35 | -8.0% | - | - | |
| Jul 15, 2020 | PCRX Pacira Biosciences, Inc. | CEO and Chairman | Sell | 12,000 | $56.88 | $682,560.00 | -6.0% | - | - |